MedChemExpress

Navitoclax

#HY-10087

24
Citing papers
423
Combined citations
Supplier page Find this product

Research areas

Telomeres, Telomerase, and Senescence12Neutrophil, Myeloperoxidase and Oxidative Mechanisms4Immune cells in cancer3Epigenetics and DNA Methylation3Ferroptosis and cancer prognosis2Neuroinflammation and Neurodegeneration Mechanisms2Advanced Breast Cancer Therapies2Cancer-related Molecular Pathways2

Papers citing this product

1
Single-cell transcriptomics identifies Mcl-1 as a target for senolytic therapy in cancer
Nature Communications·2022·116 cit.·DOI
2
Preclinical antitumor efficacy of senescence-inducing chemotherapy combined with a nanoSenolytic
Journal of Controlled Release·2020·106 cit.·DOI
3
Bcl-xL targeting eliminates ageing tumor-promoting neutrophils and inhibits lung tumor growth
EMBO Molecular Medicine·2023·34 cit.·DOI
4
Aging and injury drive neuronal senescence in the dorsal root ganglia
Nature Neuroscience·2025·32 cit.·DOI
5
The Differential Effect of Senolytics on SASP Cytokine Secretion and Regulation of EMT by CAFs
International Journal of Molecular Sciences·2024·28 cit.·DOI
6
A novel BH3 mimetic Bcl-2 inhibitor promotes autophagic cell death and reduces in vivo Glioblastoma tumor growth
Cell Death Discovery·2022·20 cit.·DOI
7
Taking Advantage of the Senescence-Promoting Effect of Olaparib after X-ray and Proton Irradiation Using the Senolytic Drug, ABT-263
Cancers·2022·17 cit.·DOI
8
Aryl hydrocarbon receptor blocks aging-induced senescence in the liver and fibroblast cells
Aging·2022·16 cit.·DOI
9
Pharmacological CDK4/6 inhibition promotes vulnerability to lysosomotropic agents in breast cancer
The EMBO Journal·2025·12 cit.·DOI
10
AI-Driven Robotics Laboratory Identifies Pharmacological TNIK Inhibition as a Potent Senomorphic Agent
Aging and Disease·2024·11 cit.·DOI

Similar products

ProductVendorPricePapers
PelcitoclaxMedChemExpress—1
ABT-737MedChemExpress——
Navitoclax — Evidence — PubIndex